Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF)

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pharmacology

Background:

• Granulocyte colony-stimulating factor (G-CSF) is crucial for treating chemotherapy-induced neutropenia.
• Current G-CSF administration leads to systemic distribution, limiting bone marrow concentration.
• Targeting G-CSF using nanoparticles aims to achieve higher, sustained bone marrow levels.

Purpose of the Study:

• To evaluate the association efficiency of human recombinant G-CSF (rhG-CSF) with polyalkylcyanoacrylate nanoparticles.
• To assess the impact of nanoparticle formulation on rhG-CSF activity and release kinetics.
• To determine the in vivo efficacy of rhG-CSF-loaded nanoparticles in a murine model.

Main Methods:

• Two preparation methods for polyalkylcyanoacrylate nanoparticles loaded with rhG-CSF were explored: anionic polymerization and precipitation.
• rhG-CSF association efficiency, surface adsorption, and colony-stimulating activity were quantified.
• In vitro release studies under seric conditions and in vivo efficacy assessments in mice were performed.

Main Results:

• Anionic polymerization allowed >66% rhG-CSF association with polyisobutyl- or polyisohexylcyanoacrylate nanoparticles, with preserved activity.
• Precipitation yielded 90% rhG-CSF association but resulted in decreased activity.
• In vitro release was progressive over 8 hours; however, in vivo studies showed no enhanced short-term effects of nanoparticle-associated rhG-CSF.

Conclusions:

• Polyalkylcyanoacrylate nanoparticles can efficiently associate with rhG-CSF, primarily via surface adsorption.
• While in vitro release is sustained, the nanoparticle formulation did not improve the short-term therapeutic efficacy of rhG-CSF in vivo.
• Further optimization of nanoparticle design and targeting strategies is needed to enhance G-CSF delivery and efficacy.